Return to content in this issue

 

Omalizumab as a therapeutic option for nasal polyposis in moderate to severe persistent allergic asthma: evidence from a prospective study in a real-world setting

Ruiz-Hornillos J1-3, Rodríguez Jiménez B4, Feliu Vila A5, Moreno Fernández A6, Hernández García MJ7, Domínguez-Ortega J8,9 on behalf the ESPLORA group

1 Allergy Service, Infanta Elena University Hospital, Valdemoro, Madrid, Spain
2Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
3Health Research Institute-Fundación Jiménez Díaz University Hospital (IIS-FJD), Madrid, Spain
4Allergy Unit. University Hospital of Getafe, Madrid, Spain
5Allergy Service, Tajo University Hospital, Aranjuez, Madrid, Spain
6Allergy Unit Virgen de la Luz Hospital, Cuenca, Spain
7Otorhinolaryngology Service, Infanta Elena University Hospital, Valdemoro, Madrid, Spain
8Allergy Department, Hospital La Paz Institute for Health Research (IdiPAZ). Madrid, Spain
9CIBER of respiratory diseases, CIBERES. Madrid, Spain

J Investig Allergol Clin Immunol 2020; Vol. 30(6)
doi: 10.18176/jiaci.0602

Key words: Omalizumab, Nasal polyposis, Moderate to severe persistent allergic asthma, Prospective study, Real-world